We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Experimental Monoclonal Antibody-Based Drug Lowers LDL-cholesterol Levels

By LabMedica International staff writers
Posted on 13 Jun 2012
An experimental cholesterol-lowering drug was found to augment the action of statins to further lower LDL-cholesterol (low-density lipoprotein – cholesterol) levels in patients with elevated cholesterol due to the hereditary condition heterozygous familial hypercholesterolemia.

The drug REGN727 was the result of collaboration between the American biopharmaceutical company Regeneron (Tarrytown, NY, USA) and the French healthcare giant Sanofi (Paris, France). More...
REGN727 is a monoclonal antibody specific for the enzyme proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9).

PCSK9 belongs to the proteinase K subfamily of the secretory subtilase family. The protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. This protein plays a major regulatory role in cholesterol homeostasis. PCSK9 binds to the epidermal growth factor-like repeat A (EGF-A) domain of the low-density lipoprotein receptor (LDLR), inducing LDLR degradation. Reduced LDLR levels result in decreased metabolism of low-density lipoproteins, which could lead to hypercholesterolemia.

A paper describing a clinical trial in which 77 patients with heterozygous familial hypercholesterolemia were treated with REGN727 plus high-dose statins, with or without ezetimibe or with only the statins (with or without ezetimibe) was published in the May 26, 2012, online edition of the journal the Lancet.

Results of the study revealed that after 12 weeks, patients taking REGN727 saw their cholesterol levels reduced by between 28.9% and 67.9% depending on their dosing regimen, compared with 10.7% among those taking a dummy treatment.

The investigators concluded, “REGN727 was well tolerated and achieved substantial further LDL-C reduction in patients with heterozygous familial hypercholesterolemia and elevated LDL-C treated with high-dose statins, with or without ezetimibe.”

Related Links:

Regeneron
Sanofi




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Platelet Function Analyzer
PL-12
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.